Imfinzi has received priority review by the FDA for the treatment of lung cancer 

AstraZeneca on Thursday the US Food and Drug Administration (FDA) said its top-selling cancer drug Imfinzi has received priority review for patients with limited-stage small-cell lung cancer in the United States.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO